Metabolic syndrome and its components as predictors of all-cause mortality and coronary heart disease in type 2 diabetic patients

Atherosclerosis

Volumn 195, Issue 1, 2007, Pages 189-194

  Protopsaltis, Ioannis ^a   Nikolopoulos, Georgios ^b   Dimou, Eftihia ^a   Brestas, Paris ^a   Kokkoris, Stelios ^a   Korantzopoulos, Panagiotis ^c   Melidonis, Andreas ^a  

^a TZANEIO GENERAL HOSPITAL OF PIRAEUS   (Greece)

^b Hellenic Center for Disease Control and Prevention   (Greece)

^c G HATZIKOSTA GENERAL HOSPITAL   (Greece)

Author keywords

Combination of components; Coronary artery disease; Diabetes; Metabolic syndrome; Morbidity; Mortality

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIABETIC PATIENT; DISEASE DURATION; EDUCATION PROGRAM; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROBABILITY; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; SEX; STATISTICAL ANALYSIS; SURVIVAL; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; CORONARY DISEASE; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK; TIME FACTORS; TREATMENT OUTCOME;

EID: 35248893880     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2006.09.019     Document Type: Article

References (30)

1. Haffner S.M. Risk constellations in patients with the metabolic syndrome: epidemiology, diagnosis, and treatment patterns. Am J Med 119 5 Suppl 1 (2006) S3-S9
2. Grundy S.M. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes world. J Am Coll Cardiol 47 (2006) 1093-1100
3. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Programme (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
4. Isomaa B., Almgren P., Tuomi T., et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24 (2001) 683-689
5. Lakka H.M., Laaksonen D.E., Lakka T.A., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288 (2002) 2709-2716
6. Sattar N., Gaw A., Scherbakova O., et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 108 (2003) 414-419
7. Hunt K.J., Resendez R.G., Williams K., et al. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 110 (2004) 1251-1257
8. Alexander C.M., Landsman P.B., Teutsch S.M., and Haffner S.M. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III, participants age 50 years and older. Diabetes 52 (2003) 1210-1214
9. Bruno G., Merletti F., Biggeri A., et al. Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study. Diabetes Care 27 (2004) 2689-2694
10. Resnick H.E., Jones K., Ruotolo G., et al. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in non diabetic American Indians: the Strong Heart Study. Diabetes Care 26 (2003) 861-867
11. McNeill A., Rosamond W.R., Girman C.J., et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 28 (2005) 385-390
12. Friedwald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
13. Hu G., and DECODE Study Group. Gender difference in all-cause and cardiovascular mortality related to hyperglycaemia and newly-diagnosed diabetes. Diabetologia 46 (2003) 608-617
14. Brun E., Nelson R.G., Bennett P.H., et al. Diabetes duration and cause-specific mortality in the Verona Diabetes Study. Diabetes Care 23 (2000) 1119-1123
15. Fox C.S., Sullivan L., D'Agostino R.B., and Wilson P.W.F. The significant effect of diabetes duration on coronary heart disease mortality. The Framingham Heart Study. Diabetes Care 27 (2004) 704-708
16. Tuomilehto J., Balkau B., Borch-Johnsen K., and Pyorala K. Prevalence of the metabolic syndrome and its relation to all cause and cardiovascular mortality in non diabetic European men and women. Arch Intern Med 164 (2004) 1066-1076
17. Ford E.S. Risks for all cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome. Diabetes Care 28 (2005) 1769-1778
18. Ko G.T., So W.Y., Chan N.N., et al. Prediction of cardiovascular and total mortality in Chinese type 2 diabetic patients by the WHO definition for the metabolic syndrome. Diabetes Obes Metab 8 (2006) 94-104
19. Sundstrom J., Riserus U., Byberg L., et al. Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality: prospective, population based cohort study. BMJ 332 (2006) 878-882
20. Malik S., Wong N.D., Franklin S.S., et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease and on all causes in United States adults. Circulation 110 (2004) 1245-1250
21. Ford E.S., and Giles W.H. A comparison of the prevalence of the metabolic syndrome using two proposed definitions. Diabetes Care 26 (2003) 575-581
22. Turner R., Millns H., Neil H., et al. Risk factors for coronary artery disease in non insulin-dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS 23). BMJ 316 (1998) 823-828
23. Bonora E., Formentini G., Calcatera F., et al. HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. Diabetes Care 25 (2002) 1135-1141
24. Adler A.I., Levy J.C., Matthews D.R., et al. Insulin sensitivity at diagnosis of type 2 diabetes is not associated with subsequent carduiovascular disease (UKPDS 67). Diabetes Med 22 (2005) 306-311
25. Guzder R.N., Gatling W., Mulle M.A., and Byrne C.D. Impact of metabolic syndrome criteria on cardiovascular disease risk in people with newly diagnosed type 2 diabetes. Diabetologia 49 (2006) 49-55
26. Klein B.E.K., Klein R., and Lee K.E. Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in Beaver Dam. Diabetes Care 25 (2002) 1790-1794
27. Golden S.H., Folsom A.R., Coresh J., et al. Risk factor groupings related to insulin resistance and their synergistic effects on subclinical atherosclerosis. The atherosclerosis risk in communities study. Diabetes 51 (2002) 3069-3076
28. Ford E.S., Giles W.H., and Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA 287 (2002) 356-359
29. Panagiotakos D., Pitsavos C., Chrysohoou C., et al. Impact of lifestyle habits on the prevalence of the metabolic syndrome among Greek adults from the ATTICA Study. Am Heart J 147 (2004) 106-112
30. Linnemann B., Voigt W., Nobel W., and Janka H.U. C-reactive protein is a strong independent predictor of death in type 2 diabetes: association with multiple facets of the metabolic syndrome. Exp Clin Endocrinol Diabetes 114 (2006) 127-134